Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis

Stopped Early termination due to operational feasibility reasons, resulting from a slow recruitment rate and logistical and financial difficulties that prevent reaching the planned sample size within the study schedule.

Conditions

• Sclerosis, Multiple
• Autoimmune Diseases of the Nervous System
• Nervous System Diseases
• Autoimmune Diseases

Interventions

• DRUG: Melatonin
• OTHER: Placebo

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla